http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113925863-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 |
| filingDate | 2020-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2023-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2023-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113925863-B |
| titleOfInvention | Application of Ivacaftor in the preparation of medicines for inhibiting novel coronavirus SARS-CoV2 |
| abstract | The invention provides the application of Ivacaftor in the preparation of drugs for inhibiting novel coronavirus SARS-CoV2, which belongs to the field of chemical medicine. The present invention mainly provides the use of a compound represented by formula I or a salt thereof in the preparation of a drug for inhibiting the new coronavirus SARS-CoV2, wherein R 1 to R 5 are independently selected from hydrogen, C 1 to C 6 alkyl , hydroxyl, carboxyl, halogen. Studies have shown that Ivacaftor has a significant inhibitory and blocking effect on the ‑1Frameshift process of the SARS‑CoV2 virus, and can effectively inhibit the replication of the SARS‑CoV2 virus, thereby inhibiting the growth of the SARS‑CoV2 virus. The novel coronavirus pneumonia caused by COVID-19. Ivacaftor can be used to prepare anti-SARS-CoV2 virus drugs, and can also be used to prepare drugs for the treatment of novel coronavirus pneumonia COVID-19 caused by SARS-CoV2 virus, and has good application prospects. |
| priorityDate | 2020-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 84.